SCHEMBL1339064

SCHEMBL1339064

Cn1c(=O)c(-c2ccc(Br)cc2)cc2c3cc(-c4nc(CN)cs4)ccc3n(C)c21

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SREBF2 Q12772 1/20 0.38
▸ ENPP2 Q13822 7/20 0.38
▸ IRAK4 Q9NWZ3 1/20 0.38
▸ LMNA P02545 5/20 0.37
▸ L3MBTL1 Q9Y468 3/20 0.37
▸ MAPT P10636 2/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ RECQL P46063 1/20 0.37
▸ ATM Q13315 1/20 0.37
▸ SMN1; SMN2 Q16637 3/20 0.34
▸ ALDH1A1 P00352 2/20 0.33
▸ GABRA1 P14867 2/20 0.32
▸ GABRG2 P18507 2/20 0.32
▸ GABRB3 P28472 2/20 0.32
▸ GABRA5 P31644 2/20 0.32
▸ GABRA3 P34903 2/20 0.32
▸ GABRA2 P47869 2/20 0.32
▸ DPP4 P27487 1/20 0.32
▸ ABCB1 P08183 1/20 0.32
▸ RXFP1 Q9HBX9 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1338038 0.90 LMNA (0.41) SREBF2ENPP2LMNAL3MBTL1MAPT
SCHEMBL1338699 0.84 ENPP2 (0.38) SREBF2ENPP2HDAC1HDAC8HDAC6
SCHEMBL1336852 0.83 SHMT1 (0.38) SREBF2IRAK4LMNAL3MBTL1KDM4E
SCHEMBL1338328 0.83 LMNA (0.39) SREBF2IRAK4LMNAL3MBTL1MAPT
SCHEMBL1339356 0.82 LMNA (0.43) SREBF2ENPP2LMNAL3MBTL1SMN1; SMN2
SCHEMBL1339172 0.79 LMNA (0.40) SREBF2ENPP2LMNAL3MBTL1MAPT
SCHEMBL1338217 0.76 SHMT1 (0.40) ENPP2LMNAL3MBTL1KDM4ESMN1; SMN2
SCHEMBL1338957 0.75 GFER (0.44) LMNAL3MBTL1MAPTKDM4ESMN1; SMN2
SCHEMBL1339424 0.73 SHMT1 (0.47) LMNAKDM4ESMN1; SMN2ALDH1A1HPGD
SCHEMBL1338195 0.73 SHMT1 (0.37) ENPP2LMNAL3MBTL1KDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063061-B2 6-(2-amino-1,3-thiazol-4-yl)-3-(2,4-dichlorophenyl)-1-methyl-1,9-dihydro-2H-pyrido[2,3-b]indol-2-one; affinity for GABAA-receptor-associated omega modulatory sites SANOFI-AVENTIS (FR) 2011-11-22 — — US disclosed
EP-1940840-B1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2010-07-21 — — EP disclosed
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof SANOFI-AVENTIS (FR) 2008-10-23 — — US disclosed
EP-1940840-A1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2008-07-09 — — EP disclosed
WO-2007045758-A1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2007-04-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof CYP11B2, CYP11B1, CYP2D6 SREBF2 2552/4885ENPP2 891/4885IRAK4 2303/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback